MCID: SPN186
MIFTS: 68

Spinal Cord Injury

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Spinal Cord Injury

MalaCards integrated aliases for Spinal Cord Injury:

Name: Spinal Cord Injury 38 76 54 59
Spinal Cord Injuries 43

Characteristics:

Orphanet epidemiological data:

59
spinal cord injury
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

Orphanet 59 ORPHA90058
ICD10 via Orphanet 34 T09.3
UMLS via Orphanet 74 C0037929

Summaries for Spinal Cord Injury

MedlinePlus : 43 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Spinal Cord Injury, also known as spinal cord injuries, is related to brain injury and prostatitis. An important gene associated with Spinal Cord Injury is RTN4IP1 (Reticulon 4 Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Pregabalin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

NINDS : 54 A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy axons -- extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis

Wikipedia : 76 A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in... more...

Related Diseases for Spinal Cord Injury

Diseases related to Spinal Cord Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
# Related Disease Score Top Affiliating Genes
1 brain injury 30.9 BDNF CASP3 GFAP IL6
2 prostatitis 30.7 IL6 TGFB1 TNF
3 myelitis 30.4 AQP4 IL6 TNF
4 traumatic brain injury 30.3 AQP4 BDNF CASP3 GFAP IL6
5 laryngitis 30.2 IL6 TGFB1 TNF
6 arteries, anomalies of 30.0 IL6 MMP9 TNF
7 end stage renal failure 29.9 IL6 TGFB1 TNF
8 transverse myelitis 29.7 AQP4 IL6 MMP9 TNF
9 multiple sclerosis 28.3 AQP4 BDNF GFAP IL6 MMP9 NOS2
10 respiratory failure 11.5
11 central cord syndrome 11.4
12 spasticity 11.4
13 paraplegia 11.3
14 syringomyelia 11.3
15 spinal shock 11.3
16 tethered cord syndrome 11.2
17 myoclonus 11.2
18 tethered spinal cord syndrome 10.9
19 acute cystitis 10.9
20 central cervical cord syndrome 10.9
21 swallowing disorders 10.9
22 scorpion envenomation 10.8 IL6 TNF
23 cervicitis 10.8
24 autoimmune inner ear disease 10.7 MMP9 TNF
25 cerebral artery occlusion 10.7 BDNF GDNF TNF
26 leukomalacia 10.7 IL6 TNF
27 meningoencephalitis 10.6 BDNF GDNF IL6
28 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 IL6 TNF
29 neuronitis 10.6
30 eales disease 10.6 IL6 NOS2 TNF
31 crimean-congo hemorrhagic fever 10.5 CASP3 IL6 TNF
32 neurogenic bladder 10.5
33 toxic encephalopathy 10.5 BDNF CASP3 GFAP
34 internal hemorrhoid 10.5 CASP3 MMP9 NOS2
35 rosacea 10.5 IL6 MMP9 TNF
36 neuroma 10.5 GDNF GFAP TGFB1
37 appendicitis 10.5 IL6 MMP9 TNF
38 critical limb ischemia 10.5 IL6 TNF
39 chorioamnionitis 10.5 IL6 MMP9 TNF
40 autoinflammation, lipodystrophy, and dermatosis syndrome 10.5 IL6 NOS2 TNF
41 status epilepticus 10.5 BDNF CASP3 GFAP
42 neuromyelitis optica 10.5 AQP4 GFAP IL6
43 bronchiolitis obliterans 10.5 IL6 MMP9 TNF
44 chlamydia 10.4 IL6 NOS2 TNF
45 neurogenic bowel 10.4
46 bacterial meningitis 10.4 IL6 MMP9 TNF
47 posterior urethral valves 10.4 IL6 TGFB1 TNF
48 depression 10.4
49 gingivitis 10.4 IL6 MMP9 TNF
50 decubitus ulcer 10.4

Graphical network of the top 20 diseases related to Spinal Cord Injury:



Diseases related to Spinal Cord Injury

Symptoms & Phenotypes for Spinal Cord Injury

GenomeRNAi Phenotypes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CASP3 GDNF NGFR NOS2 TGFB1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CASP3 GDNF MAPK1 NGFR NOS2 TGFB1

MGI Mouse Phenotypes related to Spinal Cord Injury:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.52 MMP9 KLK8 MAPK1 NGFR NOS2 NOS1
2 cellular MP:0005384 10.45 MMP9 MAPK1 NOS2 NOS1 NGFR TNF
3 homeostasis/metabolism MP:0005376 10.45 KLK8 MMP9 MAPK1 NGFR NOS2 NOS1
4 cardiovascular system MP:0005385 10.42 MMP9 MAPK1 NOS2 NOS1 NGFR TNF
5 growth/size/body region MP:0005378 10.42 MMP9 MAPK1 NGFR NOS2 NOS1 TNF
6 digestive/alimentary MP:0005381 10.4 MMP9 MAPK1 NGFR NOS2 NOS1 TGFB1
7 mortality/aging MP:0010768 10.4 KLK8 MMP9 MAPK1 NOS2 NOS1 NGFR
8 hematopoietic system MP:0005397 10.37 MMP9 MAPK1 NOS2 NOS1 NGFR TNF
9 nervous system MP:0003631 10.36 KLK8 MAPK1 NGFR MMP9 NOS2 NOS1
10 immune system MP:0005387 10.35 MMP9 MAPK1 NGFR NOS2 NOS1 TNF
11 endocrine/exocrine gland MP:0005379 10.28 MAPK1 IL6 NOS2 NOS1 TNF TGFB1
12 muscle MP:0005369 10.22 MMP9 MAPK1 NOS2 NOS1 NGFR TNF
13 integument MP:0010771 10.18 MMP9 MAPK1 IL6 NGFR NOS2 TNF
14 craniofacial MP:0005382 10.14 MAPK1 NGFR NOS2 TNF TGFB1 BDNF
15 liver/biliary system MP:0005370 10.11 MAPK1 IL6 NGFR NOS2 NOS1 TNF
16 adipose tissue MP:0005375 10.1 IL6 NOS1 NGFR NOS2 TNF TGFB1
17 reproductive system MP:0005389 10.06 MMP9 MAPK1 NOS2 NOS1 TNF TGFB1
18 hearing/vestibular/ear MP:0005377 10.04 MAPK1 NGFR BDNF AQP4 GRIN1 CASP3
19 respiratory system MP:0005388 10.03 MMP9 MAPK1 NGFR NOS2 NOS1 TGFB1
20 renal/urinary system MP:0005367 10.02 MMP9 NGFR NOS2 NOS1 TGFB1 AQP4
21 no phenotypic analysis MP:0003012 9.95 NOS1 TNF RTN4R BDNF AQP4 GRIN1
22 neoplasm MP:0002006 9.93 IL6 MMP9 MAPK1 TNF TGFB1 NOS2
23 skeleton MP:0005390 9.81 MMP9 MAPK1 IL6 NGFR NOS2 NOS1
24 vision/eye MP:0005391 9.44 MMP9 MAPK1 NGFR NOS2 NOS1 TGFB1
25 taste/olfaction MP:0005394 9.35 MAPK1 NGFR BDNF CASP3 GRIN1

Drugs & Therapeutics for Spinal Cord Injury

Drugs for Spinal Cord Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 148553-50-8 5486971
2
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
3
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
4
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
5
Midodrine Approved Phase 4,Phase 3,Phase 2 133163-28-7, 42794-76-3 4195
6
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2216-51-5 16666
7
Baclofen Approved Phase 4,Phase 2,Not Applicable 1134-47-0 2284
8
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
9
Amitriptyline Approved Phase 4 50-48-6 2160
10
Perphenazine Approved Phase 4 58-39-9 4748
11
Teriparatide Approved, Investigational Phase 4,Phase 2 52232-67-4 16133850
12 Piracetam Approved, Investigational Phase 4 7491-74-9
13
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
14
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
15
Neostigmine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-99-4 4456
16
Darifenacin Approved, Investigational Phase 4,Phase 2 133099-04-4 444031
17
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
18
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
19
Oxcarbazepine Approved Phase 4 28721-07-5 34312
20
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
21
Dextromethorphan Approved Phase 4,Phase 2 125-71-3 5360696 5362449
22
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 93-14-1 3516
23
Cycloserine Approved Phase 4 68-41-7 401 6234
24
Denosumab Approved Phase 4 615258-40-7
25
Rivaroxaban Approved Phase 4 366789-02-8
26
Trazodone Approved, Investigational Phase 4,Phase 2 19794-93-5 5533
27
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
28
Vancomycin Approved Phase 4 1404-90-6 441141 14969
29 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
31
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
32
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
33
Serine Approved, Nutraceutical Phase 4,Phase 2,Phase 3 56-45-1 5951
34 Etiracetam Investigational Phase 4 33996-58-6
35
Lactitol Investigational Phase 4 585-86-4 3871
36 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
39 calcium channel blockers Phase 4,Phase 3,Not Applicable
40 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
41 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
44 Tranquilizing Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
45 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3
46 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Vardenafil Dihydrochloride Phase 4,Phase 3
48 Vasodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
50 Anesthetics Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1047)
# Name Status NCT ID Phase Drugs
1 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
2 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
3 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
4 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
5 A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
6 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
7 Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia Unknown status NCT02379156 Phase 4 Midodrine Hydrochloride
8 Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males Completed NCT01067391 Phase 4 tadalafil;placebo
9 Assess Efficacy in Subjects With Traumatic Spinal Cord Injury Completed NCT00667966 Phase 4 Vardenafil (Levitra, BAY 38-9456), 10 mg;Placebo;Vardenafil (Levitra, BAY 38-9456), 20 mg
10 Chronic Pain in Spinal Cord Injury Completed NCT00006428 Phase 4 Amitriptyline
11 Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients Completed NCT01579500 Phase 4 Botulinum toxin type A;normal saline
12 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
13 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI) Completed NCT00826228 Phase 4 teriparatide
14 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
15 Pressure Ulcer Healing With Microcyn Completed NCT02001558 Phase 4 Microcyn
16 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
17 A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
18 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury Completed NCT00286520 Phase 4
19 Zoledronic Acid Administration in Acute Spinal Cord Injury Completed NCT02042872 Phase 4 Zoledronic acid
20 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage Completed NCT00745095 Phase 4 Neostigmine
21 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4 Oxybutynin Cl;Trospium Cl;Darifenacin Hydrogen Bromide (HBr)
22 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
23 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4 Oxybutynin transdermal system
24 Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels Completed NCT01896037 Phase 4
25 Symptom Based Treatment of Neuropathic Pain Completed NCT02180880 Phase 4 Pregabalin and Oxcarbazepine
26 Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections Completed NCT00318591 Phase 4
27 Body Temperature in Persons With Tetraplegia When Exposed to Cold Completed NCT01822535 Phase 4 Midodrine hydrochloride
28 Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia Completed NCT00507546 Phase 4 Ramelteon;Placebo
29 Evaluation of the Nursing C-Spine (Phase IV) Completed NCT01353352 Phase 4
30 C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain Completed NCT02095197 Phase 4 Triamcinolone 80mg
31 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
32 Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD Recruiting NCT02537899 Phase 4 NeuroAiD
33 Bowel Care and Cardiovascular Function After Spinal Cord Injury Recruiting NCT01567605 Phase 4 Lidocaine lubricant
34 Lower Limb Function After Spinal Cord Injury Recruiting NCT02635893 Phase 4 D-Cycloserine;Placebo
35 Enhancing STDP After Spinal Cord Injury Recruiting NCT02701777 Phase 4 Seromycin;Dextromethorphan;Seromycin Placebo;Dextromethorphan Placebo
36 Denosumab Administration After Spinal Cord Injury Recruiting NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
37 The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
38 Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Recruiting NCT01698138 Phase 4 Onabotulinumtoxin A;Placebo
39 Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury Recruiting NCT02970773 Phase 4 Rivaroxaban Oral Tablet
40 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
41 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction Recruiting NCT03169582 Phase 4 Avanafil;Sildenafil
42 Nerve Transfer Reconstruction in the Tetraplegic Upper Extremity Recruiting NCT01579604 Phase 4
43 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
44 Once Weekly GLP-1 in Persons With Spinal Cord Injury Not yet recruiting NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
45 Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
46 Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured Terminated NCT00869427 Phase 4 vitamin C
47 Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder Terminated NCT01023269 Phase 4
48 Minocycline in Acute Spinal Cord Injury (MASC) Unknown status NCT01828203 Phase 3 Minocycline;Placebo
49 Efficacy and Safety of Growth Hormone Treatment in Spinal Cord Injury Unknown status NCT01329757 Phase 3 GH;Placebo
50 SCIPA Full-On :Intensive Exercise Program After Spinal Cord Injury Unknown status NCT01236976 Phase 3

Search NIH Clinical Center for Spinal Cord Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spinal Cord Injury cell therapies at LifeMap Discovery.

Genetic Tests for Spinal Cord Injury

Anatomical Context for Spinal Cord Injury

MalaCards organs/tissues related to Spinal Cord Injury:

41
Spinal Cord, Bone, Brain, Testes, Bone Marrow, Colon, Skeletal Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spinal Cord Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Potential therapeutic candidate
5 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
6 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
7 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
8 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Spinal Cord Injury

Articles related to Spinal Cord Injury:

(show top 50) (show all 2935)
# Title Authors Year
1
Pre-operative screening for asymptomatic bacteriuria and associations with post-operative outcomes in patients with spinal cord injury. ( 29578382 )
2018
2
Pifithrin-I1 modulates microglial activation and promotes histological recovery following spinal cord injury. ( 29962076 )
2018
3
Risk factors for dysphagia after a spinal cord injury: a systematic review and meta-analysis. ( 29955090 )
2018
4
Photobiomodulation Optimization for Spinal Cord Injury Rat Phantom Model. ( 29967691 )
2018
5
Trimethylene carbonate-caprolactone conduit with poly-p-dioxanone microfilaments to promote regeneration after spinal cord injury. ( 29174588 )
2018
6
Surgical management of the neurogenic bladder after spinal cord injury. ( 29680953 )
2018
7
'<i>In a blink of an eye your life can change</i>': experiences of players sustaining a rugby-related acute spinal cord injury. ( 29976760 )
2018
8
Relationship of fitness and wheelchair mobility with encounters, avoidances, and perception of environmental barriers among manual wheelchair users with Spinal Cord Injury. ( 29981312 )
2018
9
Positive sexuality in men with spinal cord injury. ( 29967449 )
2018
10
Response to &amp;quot;The neurogenic bowel dysfunction score in patients with spinal cord injury: methodological issues in reliability and validity&amp;quot;. ( 29348689 )
2018
11
Unique sensory and motor behavior in Thy1-GFP-M mice before and after spinal cord injury. ( 29385890 )
2018
12
Medusa's Head: The Complement System in Traumatic Brain and Spinal Cord Injury. ( 28816089 )
2018
13
The Effect of Quetiapine on Treatment of Experimental Acute Spinal Cord Injury. ( 27476924 )
2018
14
The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-I+ and p27kip1 expression. ( 29436581 )
2018
15
Comparing disability between traumatic brain injury and spinal cord injury using the 12-item WHODAS 2.0 and the WHO minimal generic data set covering functioning and health. ( 29962230 )
2018
16
The neurogenic bowel dysfunction score in patients with spinal cord injury: methodological issues in reliability and validity. ( 29348690 )
2018
17
FM19G11 and Ependymal Progenitor/Stem Cell Combinatory Treatment Enhances Neuronal Preservation and Oligodendrogenesis after Severe Spinal Cord Injury. ( 29315225 )
2018
18
Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study. ( 29904191 )
2018
19
Impact of spasticity on transfers and activities of daily living in individuals with spinal cord injury. ( 29334339 )
2018
20
Inhibition of mammalian target of rapamycin complex 1 signaling by n-3 polyunsaturated fatty acids promotes locomotor recovery after spinal cord injury. ( 29436695 )
2018
21
Arm crank ergometry improves cardiovascular disease risk factors and community mobility independent of body composition in high motor complete spinal cord injury. ( 29334345 )
2018
22
Comparison of Single-Session Dose Response Effects of Whole Body Vibration on Spasticity and Walking Speed in Persons with Spinal Cord Injury. ( 29959653 )
2018
23
Outcome analyses of a multimodal treatment approach for deep pressure ulcers in spinal cord injuries: a retrospective cohort study. ( 29386657 )
2018
24
Quality of life in the subacute period following a cervical traumatic spinal cord injury based on the initial severity of the injury: a prospective cohort study. ( 29970920 )
2018
25
Coping flexibility as predictor of distress in persons with spinal cord injury. ( 29966646 )
2018
26
Through Clinical Observation: The History of Priapism After Spinal Cord Injuries. ( 29054772 )
2018
27
Baroreflex autonomic control in human spinal cord injury: Physiology, measurement, and potential alterations. ( 28844537 )
2018
28
Diffusion Tensor Imaging in Diagnosis of Post-Traumatic Syringomyelia in Spinal Cord Injury in Rats. ( 29311540 )
2018
29
Obesity cutoff values in Korean men with motor complete spinal cord injury: body mass index and waist circumference. ( 29976960 )
2018
30
Measuring the interference of pain on daily life in persons with spinal cord injury: A Rasch-validated subset of items from the Brief Pain Inventory interference scale. ( 29962059 )
2018
31
Randomized trial of concentrated proanthocyanidins (PAC) for acute reduction of bacteriuria in male veterans with spinal cord injury utilizing clean intermittent catheterization. ( 29977609 )
2018
32
Photobiomodulation improves motor response in patients with spinal cord injury submitted to electromyographic evaluation: randomized clinical trial. ( 29441450 )
2018
33
Spinal cord injury associated with cervical spinal canal stenosis: Outcomes and prognostic factors. ( 28993290 )
2018
34
Robot-assisted upper extremity rehabilitation for cervical spinal cord injuries: a systematic scoping review. ( 29334467 )
2018
35
Anatomical Feasibility of Extradural Transferring S2 and S3 Ventral Roots to S1 Ventral Root for Restoring Neurogenic Bladder in Spinal Cord Injury. ( 29470276 )
2018
36
Stigma and self-management: an Interpretative Phenomenological Analysis of the impact of chronic recurrent urinary tract infections after spinal cord injury. ( 29449969 )
2018
37
Transient Hypertension after Spinal Cord Injury Leads to Cerebrovascular Endothelial Dysfunction and Fibrosis. ( 29141501 )
2018
38
Measuring Marrow Density and Area Using Peripheral Quantitative Computed Tomography at the Tibia: Precision in Young and Older Adults and Individuals With Spinal Cord Injury. ( 28359675 )
2018
39
The experience of spasticity after spinal cord injury: perceived characteristics and impact on daily life. ( 29339776 )
2018
40
Changes in alcohol use after the onset of spinal cord injury. ( 28446059 )
2018
41
Neurogenic bowel management for the adult spinal cord injury patient. ( 29951791 )
2018
42
Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injury. ( 29569211 )
2018
43
Blockade of Interleukin-7 Receptor Shapes Macrophage Alternative Activation and Promotes Functional Recovery After Spinal Cord Injury. ( 29069618 )
2018
44
Cross-cultural adaptation and validation of the &amp;quot;Spinal Cord Injury-Falls Concern Scale&amp;quot; in the Italian population. ( 29449685 )
2018
45
Bladder irrigation with Chlorhexidine reduces bacteriuria in persons with spinal cord injury. ( 29355293 )
2018
46
Spinal cord injury with central cord syndrome from surfing. ( 29423316 )
2018
47
Conditional neuromodulation of neurogenic detrusor overactivity using transrectal stimulation in patients with spinal cord injury: A proof of principle study. ( 28666061 )
2018
48
The risk of spinal cord injury during the frozen elephant trunk procedure in acute aortic dissection. ( 29360994 )
2018
49
Syringobulbia: A delayed complication following spinal cord injury - case report. ( 29485364 )
2018
50
Scalp Acupuncture For The Treatment Of Motor Function In Acute Spinal Cord Injury: A Case Report. ( 29436375 )
2018

Variations for Spinal Cord Injury

Expression for Spinal Cord Injury

Search GEO for disease gene expression data for Spinal Cord Injury.

Pathways for Spinal Cord Injury

Pathways related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 ARG1 CASP3 GDNF GRIN1 IL6 MAPK1
2
Show member pathways
13.58 BDNF CASP3 GRIN1 IL6 MAPK1 NOS1
3
Show member pathways
13.58 BDNF CASP3 GDNF GRIN1 IL6 MAPK1
4
Show member pathways
13.32 BDNF CASP3 IL6 MAPK1 NGFR TGFB1
5
Show member pathways
13.31 CASP3 GDNF GRIN1 IL6 MAPK1 MMP9
6
Show member pathways
13.29 AQP4 BDNF CASP3 IL6 MAPK1 TGFB1
7
Show member pathways
13.05 GRIN1 MAPK1 MMP9 NOS1 NOS2 TGFB1
8
Show member pathways
12.98 BDNF CASP3 IL6 MAPK1 NGFR TNF
9
Show member pathways
12.92 MAPK1 NOS1 NOS2 TGFB1 TNF
10
Show member pathways
12.89 CASP3 GDNF IL6 MAPK1 TGFB1 TNF
11
Show member pathways
12.89 CASP3 IL6 MAPK1 MMP9 NGFR TNF
12 12.84 CASP3 IL6 MAPK1 MMP9 NOS2 TGFB1
13 12.77 BDNF CASP3 MAPK1 NGFR TGFB1 TNF
14
Show member pathways
12.72 BDNF IL6 NGFR TGFB1 TNF
15
Show member pathways
12.6 IL6 MAPK1 NOS1 NOS2 TNF
16
Show member pathways
12.55 CASP3 IL6 MAPK1 MMP9 TGFB1 TNF
17
Show member pathways
12.53 CASP3 MAPK1 NGFR TNF
18
Show member pathways
12.5 CASP3 MAPK1 NOS1 TNF
19
Show member pathways
12.45 IL6 MAPK1 TGFB1 TNF
20
Show member pathways
12.44 IL6 MAPK1 TGFB1 TNF
21
Show member pathways
12.35 CASP3 IL6 MAPK1 MMP9 TNF
22 12.32 CASP3 MAPK1 MMP9 TGFB1 TNF
23
Show member pathways
12.29 IL6 MAPK1 NOS2 TNF
24
Show member pathways
12.27 CASP3 MAPK1 NOS2 TGFB1 TNF
25
Show member pathways
12.24 IL6 MAPK1 NOS2 TNF
26 12.13 CASP3 IL6 MAPK1 NOS2 TGFB1 TNF
27
Show member pathways
12.1 BDNF IL6 MAPK1 NGFR TGFB1
28 12.07 BDNF CASP3 GRIN1 MAPK1 NGFR
29 12.01 AQP4 BDNF CASP3 GRIN1 IL6 TNF
30
Show member pathways
12 CASP3 GRIN1 NOS1 TNF
31 11.93 IL6 MMP9 NOS2 TGFB1 TNF
32 11.91 IL6 MAPK1 NOS2
33 11.89 CASP3 IL6 MAPK1 MMP9 TNF
34 11.88 CASP3 MAPK1 TGFB1
35 11.86 IL6 TGFB1 TNF
36 11.84 IL6 MAPK1 NOS2
37 11.83 MAPK1 TGFB1 TNF
38 11.83 CASP3 IL6 MAPK1 TGFB1 TNF
39 11.8 BDNF GDNF GFAP
40 11.77 IL6 TGFB1 TNF
41 11.72 CASP3 MAPK1 MMP9 NOS2
42 11.72 CASP3 IL6 MAPK1 MMP9 NOS2 TGFB1
43
Show member pathways
11.71 BDNF CASP3 NGFR RTN4R
44 11.7 CASP3 IL6 MMP9
45 11.68 IL6 MMP9 TGFB1 TNF
46
Show member pathways
11.67 BDNF MAPK1 NGFR
47 11.65 CASP3 IL6 MAPK1 NOS2 TNF
48
Show member pathways
11.64 ARG1 NOS1 NOS2
49 11.63 AQP4 ARG1 BDNF CASP3 GDNF GFAP
50 11.62 CASP3 IL6 TNF

GO Terms for Spinal Cord Injury

Cellular components related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 ARG1 BDNF GDNF IL6 KLK8 MAPK1
2 membrane raft GO:0045121 9.26 CASP3 NOS1 RTN4R TNF

Biological processes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 BDNF GDNF IL6 TGFB1 TNF
2 regulation of cell proliferation GO:0042127 9.93 NGFR NOS2 TGFB1 TNF
3 inflammatory response GO:0006954 9.92 IL6 NGFR NOS2 TGFB1 TNF
4 axon guidance GO:0007411 9.86 BDNF GDNF MAPK1 NGFR
5 response to organic substance GO:0010033 9.83 CASP3 TGFB1 TNF
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.82 CASP3 NGFR TNF
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 IL6 TGFB1 TNF
8 apoptotic signaling pathway GO:0097190 9.8 CASP3 NGFR TNF
9 response to hypoxia GO:0001666 9.8 CASP3 NOS1 NOS2 TGFB1
10 memory GO:0007613 9.79 BDNF GRIN1 KLK8
11 cellular response to organic cyclic compound GO:0071407 9.78 CASP3 TGFB1 TNF
12 MAPK cascade GO:0000165 9.77 GDNF GRIN1 MAPK1 TGFB1 TNF
13 response to glucocorticoid GO:0051384 9.76 CASP3 IL6 TNF
14 cellular response to lipopolysaccharide GO:0071222 9.76 ARG1 IL6 NOS2 TNF
15 negative regulation of neuron projection development GO:0010977 9.74 GFAP NGFR RTN4R
16 response to lipopolysaccharide GO:0032496 9.73 ARG1 CASP3 MAPK1 NGFR NOS1 NOS2
17 learning or memory GO:0007611 9.72 CASP3 GRIN1 MAPK1
18 positive regulation of apoptotic process GO:0043065 9.7 CASP3 GRIN1 IL6 MMP9 NGFR TGFB1
19 neurotrophin TRK receptor signaling pathway GO:0048011 9.66 CASP3 NGFR
20 nitric oxide biosynthetic process GO:0006809 9.65 NOS1 NOS2
21 negative regulation of fat cell differentiation GO:0045599 9.65 IL6 TGFB1 TNF
22 negative regulation of activated T cell proliferation GO:0046007 9.64 ARG1 CASP3
23 positive regulation of guanylate cyclase activity GO:0031284 9.63 NOS1 NOS2
24 negative regulation of axon regeneration GO:0048681 9.62 KLK8 RTN4R
25 negative regulation of lipid storage GO:0010888 9.6 IL6 TNF
26 Bergmann glial cell differentiation GO:0060020 9.59 GFAP MAPK1
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.58 MAPK1 TGFB1 TNF
28 positive regulation of receptor binding GO:1900122 9.54 BDNF MMP9
29 peptidyl-cysteine S-nitrosylation GO:0018119 9.51 NOS1 NOS2
30 arginine catabolic process GO:0006527 9.5 ARG1 NOS1 NOS2
31 positive regulation of mononuclear cell migration GO:0071677 9.43 TGFB1 TNF
32 response to wounding GO:0009611 9.35 ARG1 CASP3 GFAP KLK8 TGFB1
33 cytokine-mediated signaling pathway GO:0019221 9.17 CASP3 IL6 MMP9 NOS2 RTN4R TGFB1
34 negative regulation of apoptotic process GO:0043066 10.05 CASP3 GDNF IL6 MMP9 NGFR

Molecular functions related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.62 GRIN1 NGFR NOS1 NOS2
2 growth factor activity GO:0008083 9.46 BDNF GDNF IL6 TGFB1
3 FMN binding GO:0010181 9.4 NOS1 NOS2
4 arginine binding GO:0034618 9.37 NOS1 NOS2
5 NADPH-hemoprotein reductase activity GO:0003958 9.26 NOS1 NOS2
6 tetrahydrobiopterin binding GO:0034617 8.96 NOS1 NOS2
7 nitric-oxide synthase activity GO:0004517 8.62 NOS1 NOS2

Sources for Spinal Cord Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....